Project: A unique tolerance inducing therapy for the treatment of the Orphan disease Myasthenia Gravis (MG)

Toleranzia is developing a new and unique therapy for the treatment of the autoimmune Orphan disease Myasthenia Gravis. Taking advantage of the abilities of Cholera toxin to modulate the immune system, a therapeutic fusion protein that promotes induction of tolerance to incorporated disease-specific peptides has been developed. The proof of concept in an animal model will be validated in human cells; the drug substance produced and preparations for preclinical and clinical studies performed.

Acronym TolerizeMG (Reference Number: 9480)
Duration 01/04/2015 - 01/05/2016
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 2

Project partner

Number Name Role Country
20804 Toleranzia AB Coordinator Sweden
20805 UAB “Biotechnologines farmacijos centras „Biotechpharma“ Partner Lithuania
20806 Bioneer Partner Denmark
20807 Klifo A/S Partner Denmark